Pfizer Announces Agreement with Puma Biotechnology and Lyrica Success - Clinical Professionals
Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of Neratinib for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2019 San Antonio Breast Cancer Symposium | BioSpace
A New Drug on the Horizon for HER2 Breast Cancer Patients | Avise Analytics
Cancer hopeful neratinib plagued by diarrhea, analysis shows, but Puma cites a solution | Fierce Pharma
Puma Biotechnology
HER2+ Breast Cancer Patients' Access to Neratinib Expanded Through Puma's EAP
Marketing Application for Early Stage Breast Cancer Therapy Neratinib Submitted to EMA by Puma Biotechnology - Breast Cancer News
EX-99.1
Puma's Nerlynx unleashed to fight HER2+ breast cancer with 'best case' label | Fierce Pharma
Puma Biotechnology Presents Updated Findings from the TBCRC-022 Trial at the 2022 San Antonio Breast Cancer Symposium | Business Wire
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | citybiz
Puma Biotechnology | $PBYI Stock | Shares Climb Up as Company Announced FDA Approval for NERLYNX - Warrior Trading News
Why Shares in Puma Biotechnology Inc. Are Plunging | The Motley Fool
Puma Biotechnology Inc (PBYI) Stock Message Board | InvestorsHub
Neratinib Plus Capecitabine Approved for HER2-Positive Metastatic Breast Cancer
Puma Bio Bulls Win Monday's FDA Neratinib Review, Ahead of Wednesday's Advisory Panel Vote - TheStreet
LOOKING FORWARD
Neratinib in Early-Stage Breast Cancer: A Profile of Its Use in the EU | Clinical Drug Investigation
FLASCO / FDA Clears Puma Biotechnology's Nerlynx for Extended Adjuvant Treatment of HER2-positive Early-Stage Breast Cancer
Mission Accomplished – 365 Days on Nerlynx – Ela K. Browder
Why Puma Biotechnology (PBYI) Stock Is Surging Today - TheStreet
Puma Biotech Gets Favorable FDA Vote On Neratinib - Puma Biotechnology (NASDAQ:PBYI) - Benzinga
